Verastem
Markets AVMAPKI FAKZYNJA and develops small-molecule drugs for RAS/MAPK-driven cancers.
$7.16
After-hours close−0.07 (−1.01%)
At close$7.23(−2.03%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 108.54%Insiders 1.55%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 87.87M · Float 70.38M · 80.1% free float
Institutions13F, as of Jun 30, 2026
167 holders · 95.38M shares · 35 new positions · 103 increased · 39 reduced · 31 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 9.19M | 10.46% | +3.00M | Aug 7, 2026 |
| Armistice Capital, LLC | 7.02M | 7.99% | +2.43M | Aug 14, 2026 |
| RTW Investments, LP | 6.64M | 7.55% | +59.5K | Aug 14, 2026 |
| Deep Track Capital, LP | 5.74M | 6.53% | 0 | Aug 14, 2026 |
| State Street Corp | 5.13M | 5.84% | +1.62M | Aug 7, 2026 |
| Rosalind Advisors, Inc. | 3.99M | 4.54% | +1.85M | Aug 14, 2026 |
| Vanguard Capital Management LLC | 3.85M | 4.38% | +528.7K | Aug 13, 2026 |
| Nantahala Capital Management, LLC | 3.58M | 4.08% | 0 | Aug 19, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Deep Track Capital, LP | 9.99% | 7.72M | 13G | Nov 21, 2025 ↗ |
| RTW Investments, LP | 9.90% | 9.02M | 13G | May 15, 2026 ↗ |
| Barclays PLC | 8.87% | 3.95M | 13G | Mar 21, 2025 ↗ |
| Ramya Rao | 8.87% | 3.95M | 13G | Feb 14, 2025 ↗ |
| Alyeska Fund GP, LLCincl. Anand Parekh, Alyeska Investment Group, L.P. | 7.11% | 2.86M | Nov 14, 2024 ↗ | |
| BlackRock, Inc. | 6.00% | 3.68M | 13G | Oct 17, 2025 ↗ |
| State Street Corporation | 5.80% | 5.13M | 13G | Aug 7, 2026 ↗ |
| Biotechnology Value Fund L P | 5.80% | 3.24M | 13G | Aug 13, 2025 ↗ |
| Armistice Capital, LLC | 5.23% | 4.59M | 13G | May 15, 2026 ↗ |
| Polar Capital Holdings Plc | 5.09% | 3.40M | 13G | Jan 5, 2026 ↗ |
| Vanguard Capital Management | 5.03% | 4.42M | 13G | Jul 31, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Dan Paterson | director, officer: President and CEO | 589.9K | 0.67% | Aug 5, 2026 |
| Brian M. Stuglik | director | 137.1K | 0.16% | May 26, 2026 |
| Daniel Calkins | officer: Chief Financial Officer | 117.2K | 0.13% | Jun 24, 2026 |
| Michael P. Bailey | director | 108.0K | 0.12% | May 27, 2026 |
| John Johnson | director | 52.7K | 0.06% | May 26, 2026 |
| Anil Kapur | director | 52.7K | 0.06% | May 26, 2026 |
| Michelle Robertson | director | 52.7K | 0.06% | May 26, 2026 |
| Eric K. Rowinsky | director | 52.7K | 0.06% | May 26, 2026 |
| Karin Anna Tollefson | director | 52.7K | 0.06% | May 26, 2026 |
| Matthew Ros | officer: Chief Operating Officer | 50.0K | 0.06% | Apr 3, 2025 |
9 ten-percent owners hold 3.69M shares by Form 4, outside the officers-and-directors figure above · 20 people have not refiled in the last 18 months (352.7K shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 3, 2026 | Dan Patersondirector, officer: President and CEO | Sale | 1,302 | $5.81 | 589,940 |
| Jun 22, 2026 | Daniel Calkinsofficer: Chief Financial Officer | Sale · 2 lots | 4,089 | $4.18 | 117,238 |
| Jun 22, 2026 | Dan Patersondirector, officer: President and CEO | Sale | 20,871 | $4.18 | 591,242 |
| May 4, 2026 | Dan Patersondirector, officer: President and CEO | Sale | 806 | $5.82 | 612,113 |
| Feb 4, 2026 | Dan Patersondirector, officer: President and CEO | Sale | 970 | $6.69 | 612,919 |
| Jan 12, 2026 | Daniel Calkinsofficer: Chief Financial Officer | Sale | 5,039 | $7.16 | 104,719 |
| Jan 12, 2026 | Dan Patersondirector, officer: President and CEO | Sale | 10,321 | $7.16 | 400,104 |
| Dec 24, 2025 | Daniel Calkinsofficer: Chief Financial Officer | Sale | 80 | $7.86 | 109,758 |
| Dec 16, 2025 | Robert E. Gagnondirector | Sale | 283 | $9.14 | 41,678 |
| Dec 16, 2025 | Dan Patersondirector, officer: President and CEO | Sale | 393 | $9.14 | 410,425 |
CongressHouse and Senate disclosures
Not reported.